World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
57
Citations
25298
World Ranking
3577
National Ranking
309

Overview

Matthew D. Snape is affiliated with the University of Oxford in the United Kingdom. Their primary field of study is Medicine, with significant contributions across several subfields, including Infectious Diseases, Epidemiology, Microbiology, Surgery, and Immunology.

The scientist's research focuses on key topics related to infectious diseases and vaccines, including SARS-CoV-2 and COVID-19 research, respiratory viral infections, COVID-19 clinical research studies, bacterial infections and vaccines, pneumonia and respiratory infections, influenza virus research studies, and vaccine coverage and hesitancy.

Matthew D. Snape has published extensively in prominent scientific journals. Frequent publication venues include:

  • The Lancet
  • Vaccine
  • The Journal of Infectious Diseases
  • SSRN Electronic Journal
  • Nature Medicine

Selected recent papers by Matthew D. Snape include:

  • Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, 2020, The Lancet
  • Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial, 2020, The Lancet
  • Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection, 2021, Nature Medicine
  • Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials, 2021, The Lancet
  • Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial, 2021, The Lancet

The scientist has collaborated frequently with peers including Andrew J. Pollard, Parvinder K. Aley, Elizabeth Clutterbuck, Hannah Robinson, and Yama F Mujadidi.

Best Publications

  • Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

    M Voysey;Clemens Sac.;S A Madhi;L Y Weckx

  • Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

    P M Folegatti;K J Ewer;P K Aley;B Angus

  • Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

    M Voysey;S A Costa Clemens;S A Madhi;L Y Weckx

  • Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

    Unknown

  • Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

    M N Ramasamy;A M Minassian;K J Ewer;A L Flaxman

  • Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.

    Shuo Feng;Daniel J. Phillips;Thomas White;Homesh Sayal

  • Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

    Pedro M Folegatti;Katie J Ewer;Parvinder K Aley;Brian Angus

  • Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

    Katherine R W Emary;Tanya Golubchik;Parvinder K Aley;Cristina V Ariani

  • T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

    K J Ewer;Barrett;S Belij-Rammerstorfer;H Sharpe

  • Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

    Xinxue Liu;Robert H Shaw;Arabella S V Stuart;Melanie Greenland

  • Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

    Alasdair P S Munro;Alasdair P S Munro;Leila Janani;Victoria Cornelius;Parvinder K Aley

  • Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants

    Shabir A Madhi;Fernando P Polack;Pedro A Piedra;Flor M Munoz

  • Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules: A Randomized Controlled Trial

    Nicoletta Gossger;Matthew D. Snape;Ly-Mee Yu;Adam Finn

  • SARS-CoV-2 Variants and Vaccines.

    Philip R Krause;Thomas R Fleming;Ira M Longini;Richard Peto

  • Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized Clinical Trial

    Iain D. Milligan;Malick M. Gibani;Richard Sewell;Elizabeth A. Clutterbuck

  • Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum

    Unknown

  • Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.

    Jamie Findlow;Ray Borrow;Matthew D. Snape;Tom Dawson

  • Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

    Unknown

  • Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

    Barrett;S Belij-Rammerstorfer;C Dold;K J Ewer

  • Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum

    Unknown

  • Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial

    Robert C Read;David Baxter;David R Chadwick;Saul N Faust;Saul N Faust

  • Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.

    Robert H Shaw;Arabella Stuart;Melanie Greenland;Xinxue Liu

  • Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

    Matthew D. Snape;Kirsten P. Perrett;Karen J. Ford;Tessa M. John

  • Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

    Claire S Waddington;W T Walker;C Oeser;A Reiner

  • Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine (preprint)

    Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A.;Weckx, Lily Yin, Folegatti, Pedro M.;Parvinder K. Aley;Angus, Brian John, Baillie, Vicky, Barnabas, Shaun L.

Frequent Co-Authors

Andrew J. Pollard
Andrew J. Pollard University of Oxford
Saul N. Faust
Saul N. Faust University Hospital Southampton NHS Foundation Trust
Adam Finn
Adam Finn University of Bristol
Paul T. Heath
Paul T. Heath St George's, University of London
Shamez N. Ladhani
Shamez N. Ladhani UK Health Security Agency
Nick Andrews
Nick Andrews Salk Institute for Biological Studies
Ray Borrow
Ray Borrow Manchester Royal Infirmary
Katie J. Ewer
Katie J. Ewer University of Oxford
Teresa Lambe
Teresa Lambe University of Oxford
Sarah C. Gilbert
Sarah C. Gilbert University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, related healthcare fields offer diverse educational and career options. Many professionals pursue advanced nursing roles, such as becoming a nurse practitioner, which combine clinical expertise with specialized knowledge.

If flexibility is a priority, exploring the easiest online nurse practitioner programs can provide a great starting point. These programs often balance accessibility and quality education for busy students.

Mental health nursing is another in-demand area. Students considering this path might review reputable pmhnp programs online with best clinical placement to find programs that emphasize hands-on experiences and job placement success.

Cost can be a deciding factor for many. To find cost-effective options, researching the cheapest psychiatric nurse practitioner programs allows students to invest smartly in their education without compromising outcomes.

Career outlook is equally important. Knowing the dnp salary by specialty provides insight into potential earnings, aiding informed decisions about specialization and geographic location.

Best Scientists Citing Matthew D. Snape

Trending Scientists

Recently Published Articles